Stockscreener 앱 받기
4.17
3.99%
0.16
시간 외 거래:
4.20
0.03
+0.72%
전일 마감가:
$4.01
열려 있는:
$4.09
하루 거래량:
2.52M
Relative Volume:
1.10
시가총액:
$366.43M
수익:
$30.91M
순이익/손실:
$-209.47M
주가수익비율:
-1.253
EPS:
-3.3279
순현금흐름:
$-147.13M
1주 성능:
+10.90%
1개월 성능:
-3.47%
6개월 성능:
-47.61%
1년 성능:
-21.47%
1일 변동 폭
$4.09
$4.40
1주일 범위
$3.67
$4.40
52주 변동 폭
$3.55
$11.24
Verastem Inc Stock (VSTM) Company Profile
명칭
Verastem Inc
전화
(781) 292-4200
주소
117 KENDRICK STREET, NEEDHAM, MA
Compare VSTM vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
4.17 | 351.49M | 30.91M | -209.47M | -147.13M | -3.3279 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-12 | 재개 | BTIG Research | Buy |
| 2026-02-04 | 개시 | H.C. Wainwright | Buy |
| 2025-10-16 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-04-10 | 개시 | Jefferies | Buy |
| 2025-03-24 | 재확인 | H.C. Wainwright | Buy |
| 2024-12-31 | 재확인 | BTIG Research | Buy |
| 2024-09-30 | 개시 | Guggenheim | Buy |
| 2023-11-21 | 재개 | BTIG Research | Buy |
| 2023-09-27 | 개시 | B. Riley Securities | Buy |
| 2023-06-15 | 업그레이드 | Mizuho | Neutral → Buy |
| 2022-09-07 | 재개 | Alliance Global Partners | Buy |
| 2022-04-29 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-04-14 | 개시 | RBC Capital Mkts | Outperform |
| 2022-03-09 | 개시 | Truist | Buy |
| 2021-07-01 | 개시 | Alliance Global Partners | Buy |
| 2021-05-24 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2019-06-20 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2019-05-10 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-07-13 | 개시 | BTIG Research | Buy |
| 2018-05-02 | 개시 | Seaport Global Securities | Buy |
| 2018-03-08 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-09-07 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-13 | 개시 | Oppenheimer | Outperform |
| 2017-03-24 | 재확인 | H.C. Wainwright | Buy |
| 2015-09-29 | 다운그레이드 | Cantor Fitzgerald | Buy → Hold |
| 2015-09-29 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2015-09-29 | 다운그레이드 | Jefferies | Buy → Hold |
| 2015-09-29 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2015-09-28 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2015-09-28 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2015-09-09 | 개시 | Raymond James | Strong Buy |
| 2015-05-12 | 재확인 | UBS | Buy |
| 2015-04-08 | 개시 | H.C. Wainwright | Buy |
| 2015-01-23 | 재확인 | ROTH Capital | Buy |
| 2014-07-08 | 재개 | Oppenheimer | Perform |
| 2014-02-11 | 개시 | Mizuho | Buy |
모두보기
Verastem Inc 주식(VSTM)의 최신 뉴스
Early data on new KRAS cancer pill to be detailed June 23 - Stock Titan
Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), Jazz Pharmaceuticals (JAZZ) and Humana (HUM) - The Globe and Mail
Why Did Verastem Stock Jump After-Hours Despite An Earnings Miss? - Stocktwits
VSTM Technical Analysis & Stock Price Forecast - Intellectia AI
Verastem’s VS-7375 receives FDA fast track status for lung cancer - Investing.com UK
Verastem announces FDA Fast Track designation for VS-7375 - TipRanks
Verastem, Inc. receives U.S. FDA fast track for KRAS G12D inhibitor in NSCLC treatment - Traders Union
Verastem (VSTM) Surges 11% Following FDA Fast Track Designation - GuruFocus
Verastem’s VS-7375 receives FDA fast track status for lung cancer By Investing.com - Investing.com South Africa
Verastem (VSTM) Receives Fast Track Designation for Cancer Treat - GuruFocus
Verastem stock rises on FDA fast track for lung cancer drug - Investing.com Canada
Verastem Initiates Phase 2 Target-D 202 Trial For Advanced NSCLC - TradingView
Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung - Business Wire
Verastem Inc stock (US92335V1008): Nasdaq-listed oncology player steadies around late-May levels - AD HOC NEWS
VSTM Stock Price, Quote & Chart | VERASTEM INC (NASDAQ:VSTM) - ChartMill
Mizuho Securities Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Verastem (VSTM) Declines 2.5% as Biotech Sector Headwinds PersistPullback Trade - thelegaladvocate.com
Verastem (NASDAQ: VSTM) director receives 108,000 restricted stock units - Stock Titan
New Verastem (NASDAQ: VSTM) director files initial Form 3 ownership - Stock Titan
[144] Verastem, Inc. SEC Filing - Stock Titan
Biopharma Verastem Oncology joins Jefferies healthcare fireside chat June 3 - Stock Titan
Verastem Oncology to Present at Jefferies Healthcare Conference - marketscreener.com
Verastem: Robert Gagnon Stepped Down From Board Following End of Term on May 21 >VSTM - Moomoo
H.C. Wainwright Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Director at Verastem (VSTM) receives 36,000 RSUs as equity award - Stock Titan
Director Brian Stuglik (VSTM) awarded 36,000 Verastem RSUs with 2026–2027 vesting - Stock Titan
Verastem (NASDAQ: VSTM) awards 36,000 RSUs to director Rowinsky - Stock Titan
Verastem (VSTM) director Michelle Robertson awarded 36,000 RSUs - Stock Titan
Verastem (VSTM) director Anil Kapur receives 36,000 RSU equity award - Stock Titan
Verastem (VSTM) director awarded 36,000 RSUs vesting through 2027 - Stock Titan
Verastem (VSTM) director gets 36,000 RSU award vesting through 2027 - Stock Titan
Verastem Oncology Appoints Michael P. Bailey to Board of Directo - GuruFocus
Verastem (VSTM) stockholders back board slate, equity plans and auditor at 2026 meeting - Stock Titan
Verastem Oncology appoints Michael Bailey to board By Investing.com - Investing.com Australia
Verastem Oncology appoints Michael Bailey to board - Investing.com
AVEO CEO Michael Bailey joins Verastem board, rare cancer focus - Stock Titan
Verastem Q1 2026 Earnings: Narrower-than-Expected Loss Beats Estimates; Stock Edges HigherEnergy Earnings Report - thelegaladvocate.com
Verastem (VSTM) Q1 2026 Earnings: Why the Beat MattersEarnings Seasonality - thelegaladvocate.com
Verastem Q1 earnings call highlights - MSN
Verastem Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Cancer Stocks That Are Advancing the Future of Oncology Care - TradingView
Verastem (VSTM) Loses 34.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Verastem Q3 2025 Earnings Preview - MSN
Foresite (VSTM) holds 3,146,631 shares, reporting 3.6% stake - Stock Titan
Armistice Capital 5.23% stake in Verastem (VSTM) via managed fund - Stock Titan
RTW Funds, Roderick Wong Report 9.99% of Verastem (VSTM) - Stock Titan
Balyasny-affiliated holders report 1.36M shares in Verastem (VSTM) - Stock Titan
Verastem Oncology announces management changes - MSN
VSTM Maintained by Mizuho -- Price Target Lowered to $14.00 - GuruFocus
MSN Money - MSN
Mizuho Adjusts Price Target on Verastem to $14 From $16, Maintains Outperform Rating - Moomoo
Verastem Inc (VSTM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Verastem Inc 주식 (VSTM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Paterson Dan | President and CEO |
May 04 '26 |
Sale |
5.82 |
806 |
4,691 |
612,113 |
| Paterson Dan | President and CEO |
Feb 04 '26 |
Sale |
6.69 |
970 |
6,489 |
612,919 |
2.60%
0.94%
자본화:
|
볼륨(24시간):